The effect of varying degrees of hepatic impairment on the single dose safety and pharmacokinetic profile of lurasidone: an open-label phase I single dose non-randomised oral administration study.
Phase of Trial: Phase I
Latest Information Update: 16 Jan 2012
At a glance
- Drugs Lurasidone (Primary)
- Indications Bipolar disorders; Major depressive disorder; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Dainippon Sumitomo Pharma
- 16 Jan 2012 Additional locations identified as reported by ISRCTN: Current Controlled Trials.
- 27 Apr 2009 New trial record